MedDevice by Design with Mark Drlik and Ariana Wilson
Resources

Clinical Prototypes for Human Use: What You Need to Know

YouTube video thumbnail

At some point in development, someone asks the question: can we put this on a person yet?

It sounds straightforward. It isn’t. The answer depends on what you’re trying to learn, what the device actually does, and whether anyone, a clinician, an IRB, or the FDA, agrees that the risk is worth it.

In this episode of MedDevice by Design, Ariana Wilson and Mark Drlik walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.

The First Question Isn’t “Is It Ready?” It’s “What Are You Trying to Answer?”

Before anything else, the intent of the prototype defines everything downstream. Are you collecting data for a marketing claim? Testing whether a form factor works in a surgical environment? Validating that a device survives a specific biological transit? Each of those questions pulls you down a different path in terms of controls, approvals, and documentation.

Significant Risk vs Non-Significant Risk

The regulatory designation matters more than most teams expect early in development. Significant risk devices get escalated to the FDA through an Investigational Device Exemption. Non-significant risk devices are reviewed by an IRB. An ingestible capsule, as Mark explains, often lands in the non-significant risk category, even though someone is swallowing it. That classification isn’t intuitive, and getting it wrong can derail a study.

Maturity and Change Control

Running a clinical study on a device you can’t describe precisely is a problem you won’t notice until later. If four versions of a device were tested and you don’t have a record of what each one was, the data you collected may not hold up. Change control for clinical prototypes isn’t bureaucracy. It’s what makes the data defensible.

The episode covers form models, ingestible capsules, and a high-risk spinal delivery cannula as concrete examples of how these factors play out across very different device types.

One engineer works hands-on with this board's internals, carrying it from design through bring-up

When one team designs, lays out, and brings up a board, knowledge sticks. Splitting that work across specialists looks efficient but creates the risk it’s meant to avoid.

AI coding agents support this engineer as he reviews code and a workflow diagram on a call

AI coding agents like Claude and Codex are helping EE teams turn concepts into tested hardware in weeks, not months, without adding a new vendor or software dependency.

An EE partner explains an electrical architecture decision to the client team during design review

Choosing an EE partner is a program risk decision, not a staffing decision. Early architecture choices carry through to certification, and the wrong partner can cost far more than their hourly rate suggests.

PCB stack-up planning happens here, as an engineer reviews routed copper layers on a wide monitor

PCB stack-up shapes signal integrity, EMC performance, and manufacturability long before layout begins. Getting layers and reference planes right avoids costly redesigns later.